TABLE 1.
Schedule of diagnostic data collection in Cohort 1 and Cohort 2 in the prospective multicenter cohort study (COVID-19 in German competitive sports: Protocol for a prospective multicenter cohort study; Germany, 2020).
| Cohort 1 | Cohort 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Time point | t 0 | t 1 | t 2 | t 3 | t 0 | t 1 | t 2 | t 3 | t 4 |
| Month | 0 | 6 | 12 | 18 | 0 | 6 | 12 | 18 | 24 |
| Assessments | |||||||||
| Screening and study inclusion | X | X | |||||||
| Questionnaires | |||||||||
| COVID-19 specific questionnaire | |||||||||
| - Prior/intermediate SARS-CoV-2 testing | X | X | X | X | X | X | X | X | X |
| - Contact situations with SARS-CoV-2 positive subjects | X | X | X | X | X | X | X | X | X |
| - Prior/intermediate acute symptoms of infection | X | X | X | X | X | X | X | X | X |
| - Experience of unusual/chronic symptoms | X | X | X | X | X | X | X | X | X |
| - Necessity and duration of quarantine | X | X | X | X | X | X | X | X | X |
| - SARCS-CoV-2 vaccination state | X | X | X | X | X | X | X | X | X |
| - Actual exercise tolerance and performance | X | X | X | X | X | X | X | X | X |
| Anamnesis | |||||||||
| - Medical history | X | X | X | X | X | ||||
| - Training report | X | X | X | X | X | X | X | X | |
| - Family history | X | X | X | X | X | ||||
| - Medication | X | X | X | X | X | ||||
| - Dietary habits/dietary supplements | X | X | X | X | X | ||||
| Medical examination | |||||||||
| Anthropometry | |||||||||
| - Height, weight, body mass index | X | X | X | X | X | ||||
| - Percent body fat | X | X | X | X | X | ||||
| Physical examination | X | X | X | X | X | ||||
| Blood sampling and analyses | |||||||||
| Blood analyses | |||||||||
| - Blood cell and differential cells counts, C-reactive protein, liver enzymes, creatinine, ferritin, troponin a , | X | X | X | X | X | ||||
| d-dimers a , urine protein | X | X | X | X | |||||
| - SAR-CoV-2 antibody testing | X | X | X | X | X | ||||
| - Biosampling (plasma and serum) | X | X | X | X | X | ||||
| - Isolation of PBMC b (optional) | X | X | X | X | X | ||||
| Cardiorespiratory diagnostics | |||||||||
| Twelve-lead-resting electrocardiogram (ECG) c | X | X | X | X | X | ||||
| Resting blood pressure | X | X | X | X | X | ||||
| Resting spirometry | |||||||||
| - Static lung variables d | X | X | X | X | X | ||||
| - Dynamic lung variables e | X | X | X | X | X | ||||
| Echocardiography | |||||||||
| - Morphology, left and right heart dimensions f | X | X | X | X | X | ||||
| - Left and right heart systolic and diastolic function g | X | X | X | X | X | ||||
| - Strain analysis (optional) | X | X | X | X | X | ||||
| - Doppler analysis h | X | X | X | X | X | ||||
Only if individually indicated.
PBMC, peripheral blood mononuclear cells.
Interpretation of the ECG of athletes according to [26].
Inspiratory vital capacity (IVC), Forced vital capacity (FVC).
One-second vital capacity (FEV1), Tiffenau–index (FEV1/FVC), peak exspiratory flow (PEF), maximum exspiratory flow at 75% FVC (FEF75%) and 25–75% FVC (FEF25-75%).
Left ventricular enddiastolic diameter (LV-EDD), left ventricular endsystolic diameter (LV-ESD), Right ventri-cular enddiastolic diameter (RV-EDD), mode), enddiasystolic volume (EDV), endsystolic volume (ESV) left and right atrial dimensions (planimetric and M-mode), heart volume (HV, absolute and relative). Basal right ventricular diameter (RVD1), systolic septal thickness (LV-STs), diasystolic septal thickness (LV-STd), systolic posterior wall thickness (LV-PWs), diastolic systolic posterior wall thickness (LV-PWs), LV mass (LVM), LV mass index (LVMi), signs and dimension of pericardial effusion.
Fractional shortening (FS), ejection fraction (EF, by ESD and EDV, according Simpson), regional wall motion, tricuspid annular plane systolic excursion (TAPSE), E-wave, A-wave, E/A-ratio, E′-wave septal, E′- wave lateral and E/E′– wave ratio.
Colour-, PW- and CW-doppler of heart valves, maximum systolic pulmonal artery pressure via maximum tricuspidal regurgitation velocity (maximum PAPsys).